All Industries

Top Drug Discovery Companies

234 Drug Discovery companies, sorted by total funding raised.

AsymchemIPO

Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.

Tianjin, China5001–10000Healthcare, Biotech
Private Equity·$2.3B·Feb 2020
Treeline Biosciences

Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...

Watertown, United States51–200Biotech, Drug Discovery
Extension Round·$1.2B·Sep 2025
Curie.Bio

Biotech venture firm and therapeutics accelerator that invests at seed stage and acts as a drug d...

Boston, United States1–10Biotech, Drug Discovery
Seed·$1.2B·Jan 2025
Abogen Biosciences

China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.

Suzhou, China201–500Biotech, mRNA Therapeutics
Extension Round·$1.1B·Nov 2021
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Drug Discovery
Series D·$1.1B·Feb 2025
Enveda Biosciences

Uses AI to analyze natural chemistry and accelerate discovery of new medicines for biopharma and ...

Boulder, United States201–500Artificial Intelligence, Biotech
Series D·$740.0M·Sep 2025
FogPharma

Biopharmaceutical company pioneering Helicon peptide drugs to target previously undruggable prote...

Cambridge, United States51–200Biotech, Drug Discovery
Series F·$694.0M·Jan 2025
Mirador Therapeutics

Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...

San Diego, United States11–50Biotech, Drug Discovery
Series B·$650.0M·Oct 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private Equity·$647.0M·Feb 2026
Alto Pharmacy

Digital full-service pharmacy offering prescription delivery, medication management, and speciali...

San Francisco, United States501–1000Drug Discovery, Healthcare
Venture Unknown·$620.0M·Sep 2023
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series B·$612.0M·Oct 2022
Relay TherapeuticsIPO

Clinical-stage precision medicines company using protein-motion-driven drug discovery to design s...

Cambridge, United States51–200Biotech, Drug Discovery
Series C·$520.0M·Dec 2018
GenentechIPO

Biotechnology company that discovers and develops medicines for serious, life-threatening disease...

San Francisco, United States10001+Biotech, Drug Discovery
Corporate Round·$492.3M·Feb 1990
Kallyope

Kallyope leverages unique insights into neural signaling pathways to develop innovative medicines...

New York, United States51–200Biotech, Drug Discovery
Grant·$487.2M·May 2023
X4 PharmaceuticalsIPO

Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a ran...

Boston, United States51–200Biotech, Drug Discovery
Series C·$446.8M·Oct 2025
Verve TherapeuticsAcquired

Develops one-time in vivo gene-editing medicines to prevent and treat atherosclerotic cardiovascu...

Boston, United States201–500Biotech, Drug Discovery
Series C·$428.5M·Oct 2024
Vividion TherapeuticsAcquired

Vividion Therapeutics is a Bayer-owned biopharmaceutical company using chemoproteomics-based drug...

San Diego, United States201–500Biotech, Drug Discovery
Series C·$368.0M·Feb 2021
Umoja

Develops in vivo CAR T cell therapies that generate CAR T cells inside patients to treat cancer.

Seattle, United States201–500Biotech, Drug Discovery
Series C·$363.0M·Jan 2025
Ventus Therapeutics

Clinical-stage biopharmaceutical company using structural biology and computational chemistry to ...

Montreal, Canada11–50Biotech, Drug Discovery
Grant·$360.1M·Apr 2023
Neuron23

Clinical-stage biotech developing precision medicines for genetically defined Parkinson’s disease...

South San Francisco, United States11–50Biotech, Drug Discovery
Series D·$310.0M·Jun 2025
Arbor Biotechnologies

Develops next-generation gene editing therapeutics for genetic diseases, advancing liver and CNS ...

Cambridge, United States51–200Biotech, Drug Discovery
Series C·$304.5M·Mar 2025
LifeMine Therapeutics

Clinical-stage biopharma mining fungal genomes to discover genetically-encoded small molecules fo...

Cambridge, United States51–200Biotech, Drug Discovery
Venture Unknown·$300.0M·Jan 2025
AbSciIPO

Generative AI drug creation platform for designing and developing biologics

Vancouver, United States201–500Artificial Intelligence, Biotech
Growth Equity·$279.5M·Aug 2025
Frontier Medicines

Clinical-stage precision-medicine biotech using chemoproteomics and AI to discover covalent small...

San Francisco, United States51–200Biotech, Drug Discovery
Extension Round·$255.5M·Jun 2024
Vir BiotechnologyIPO

Clinical-stage biotech developing antibody- and T-cell engager-based therapeutics for infectious ...

San Francisco, United States201–500Biotech, Drug Discovery
Growth Equity·$250.0M·Oct 2024